QX Pharmaceuticals Announces QX004N/HS-20137 Enters Phase III Trial for Psoriasis, Receives RMB 58 Million Milestone Payment from Hansoh Pharma
Qyuns
Developer of Biologics for Autoimmune and Allergic Diseases
Hansoh Pharma
Pharmaceutical Research, Production, and Sales
Recently, QX004N / HS-20137, jointly developed by Jiangsu Quanxin Biopharmaceutical Co., Ltd. (hereinafter referred to as "Quanxin Bio" or "the Company", 2509.HK) and Hansoh Pharmaceutical Group Company Limited (hereinafter referred to as "Hansoh Pharma", 3692.HK), has entered the Phase III clinical trial stage for psoriasis (Psoriasis, Ps).Become the fourth product in Quanxin Bio's pipeline to successfully enter Phase III clinical trials. The company has received a total of RMB 58 million from Hansoh Pharma as milestone payments for the Ps Phase III and other payments under the licensing agreement.
In April 2024, Quanxin Biotech entered into an exclusive licensing agreement with Hansoh (Shanghai) Health Technology Co., Ltd., a wholly-owned subsidiary of Hansoh Pharma, for the development, production, and commercialization of QX004N in mainland China, Taiwan, Hong Kong, and Macao.
QX004N Injection (Sample Image)
QX004N is a recombinant humanized IgG1 monoclonal antibody that specifically binds to human IL-23. By specifically binding to the p19 subunit of human IL-23, it blocks the interaction between extracellular IL-23 and the IL-23 receptor on the cell surface, inhibiting the release of pro-inflammatory cytokines and chemokines mediated by IL-23, thereby achieving therapeutic effects.
Psoriasis is a chronic, recurrent, inflammatory disease that primarily affects the skin and joint systems. Currently, it cannot be cured and requires long-term or even lifelong treatment. Plaque psoriasis accounts for about 80%-90% of all psoriasis patients, being the most common type of psoriasis. At present, the treatment of psoriasis in China has entered the era of biologics, which have significant advantages over traditional treatments in terms of onset time, efficacy, safety, and treatment duration. Biologics have played a positive and effective role in treating severe, refractory, and special types of psoriasis. Among them, interleukin inhibitors show better efficacy and safety compared to TNF-α inhibitors, such as IL-12/23 inhibitors, IL-17A inhibitors, and IL-23p19 inhibitors.
About Quanxin Biologics
Quanxin Biologics (2509.HK), established in 2015, is a high-tech enterprise fully dedicated to the biologic therapies for autoimmune and allergic diseases. Based on an integrated layout of research and development, manufacturing, and commercial collaboration, we are well-positioned to fully unlock the commercial value of our pipeline products. Meanwhile, through the efficient development of a series of long-acting bispecific antibody products, we continue to solidify our leading position in the autoimmune field and enhance the treatment standards for related diseases. Guided by the development philosophy of "innovating for the majority of patients," the company strives to address issues of drug accessibility and affordability within its areas of focus. It has now built a product pipeline that includes multiple innovative candidates, among which one product has been approved for marketing, three are in Phase III clinical trials, and three others are in Phase II and Phase I clinical trials respectively. Multiple long-acting bispecific antibodies are under continuous development, targeting indications such as psoriasis, atopic dermatitis, ankylosing spondylitis, asthma, chronic obstructive pulmonary disease (COPD), and inflammatory bowel disease across four major therapeutic areas: dermatology, rheumatology, respiratory, and gastroenterology. Quanxin Biologics is one of the leading companies in China in the fields of autoimmune and allergic diseases. For more information, please visit: https://www.qyuns.net/.
Forward-Looking Statements
This press release may contain certain forward-looking statements which are subject to significant risks and uncertainties. Any statements made using terms such as "expect," "believe," "forecast," "anticipate," "plan," "intend," and other similar expressions related to our company are considered forward-looking statements. Our company is under no obligation to continuously update these predictive statements. These forward-looking statements are based on the current views, assumptions, expectations, estimates, forecasts, and understandings of our management regarding future events at the time the statements are made, and they do not constitute a guarantee of future performance or a reliable indicator of future results. You are hereby explicitly cautioned not to rely on any forward-looking statements. Forward-looking statements are subject to various risks, uncertainties, and other factors (including but not limited to general market conditions, regulatory changes, geopolitical tensions, or limitations and changes in data), some of which are beyond the control of our company and difficult to predict. Therefore, due to future changes and developments in our business, competitive environment, political, economic, legal, and social conditions, actual results may differ significantly from the information contained in the forward-looking statements. Our company, its directors, and employees shall not be obligated to update, modify, or supplement any such forward-looking statements, nor shall they bear any liability arising from the failure of any forward-looking statements to materialize or becoming inaccurate.
*This news aims to share the frontier progress information of the company (or partners) R&D work, not for advertising purposes, and does not recommend any drugs and/or indications.
Previous Review
